EMBC Embecta Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1872789 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY3.5%
Revenue 3-yr CAGR-2.9%
Net income 3-yr CAGR22.8%
Margins
Gross margin59.0%
Operating margin21.9%
Net margin8.6%
FCF margin16.2%
EBITDA margin26.3%
Returns
ROE—
ROA7.2%
ROIC (approx.)26.2%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets148.4%
Debt / equity—
Current ratio1.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.99x
Accruals ratio-7.1%
Payout ratio31.1%
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.08B | $1.12B |
| Cost of revenue | $403.60M | $387.90M |
| Gross profit | $676.80M | $735.20M |
| R&D expense | $37.30M | $78.80M |
| SG&A expense | $332.00M | $365.10M |
| Operating income | $242.10M | $166.80M |
| Pretax income | $136.30M | $44.20M |
| Income tax | $40.90M | -$34.10M |
| Net income | $95.40M | $78.30M |
| EBITDA | $282.80M | $203.00M |
| EPS (basic) | 1.64 | 1.36 |
| EPS (diluted) | 1.62 | 1.34 |
| Dividends declared per share | 0.60 | 0.60 |
| Weighted avg. shares (diluted) | 58.91M | 58.33M |
| Balance sheet | ||
| Cash & equivalents | $225.50M | $274.20M |
| Receivables | $145.60M | $193.00M |
| Inventory | $178.60M | $171.50M |
| Current assets | $631.40M | $761.00M |
| PP&E, net | $257.20M | $290.40M |
| Goodwill | $15.40M | $15.60M |
| Intangibles | $7.00M | $8.10M |
| Total assets | $1.09B | $1.29B |
| Current liabilities | $261.50M | $374.00M |
| Short-term debt | $9.50M | $9.50M |
| Long-term debt | $1.39B | $1.57B |
| Total debt | $1.40B | $1.57B |
| Total liabilities | $1.74B | $2.02B |
| Shareholders' equity | -$650.60M | -$738.30M |
| Net debt | $1.17B | $1.30B |
| Shares outstanding | 58.50M | 57.71M |
| Cash flow statement | ||
| Operating cash flow | $191.70M | $35.70M |
| Capital expenditure | $9.30M | $15.80M |
| Free cash flow | $182.40M | $19.90M |
| Investing cash flow | -$9.30M | -$15.80M |
| Financing cash flow | -$226.70M | -$73.40M |
| Depreciation & amortization | $40.70M | $36.20M |
| Stock-based compensation | $31.60M | $26.30M |
| Dividends paid | $35.00M | $34.50M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.